Abstract
ObjectiveAlthough adjuvant trastuzumab-based treatment (TBT) improves survival for patients with HER2-positive early invasive breast cancer (EIBC), risk of toxicity grows as patient age increases. We examined use of TBT and...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have